Pharmaceutical Pathways Speakers

BioOhio is proud to present an amazing line up of speakers, moderators, and panelists for Pharmaceutical Pathways. Below you will find brief biographies and links to their respective organizations.

(in order of appearance)

Southwest Ohio, May 21

8:30 – Introduction & Opening Remarks

John F. Lewis, Jr., President & CEO, BioOhio

John F. Lewis, Jr., is a 4th generation Ohioan, his family tracing Ohio roots to the mid 1800s. He is a licensed attorney with experience in international business, venture capital investments and economic development. John is an outspoken advocate for industry led, market facing academic/industry collaborations. During the last 16+ years with BioOhio, John has helped raise nearly $1 billion for Ohio bioscience entities. He was a founding partner of the First Fifty Fund and Ohio TechAngel Fund both based in Columbus. John has more than 18 years international experience, lived in Jamaica, Korea and China, the latter two with Perkin Elmer, while traveling to more than 42 others. John is a graduate of Miami (Ohio) University and Capital University Law School.

8:35 – Advancements in Drug Discovery & Development – Academia

Moderated by Elliot Reed, EIR, Faculty – College of Graduate Studies | REDIzone Program Manager, Northeast Ohio Medical University

Elliot Reed is responsible for creating a culture of innovation and entrepreneurship at Northeast Ohio Medical University and leading the public-private interactions between regional start-up life science companies and University researchers. His Entrepreneur in Residence responsibilities focus on providing early-stage commercial planning and fundraising support for REDizone companies and NEOMED faculty/students interested in start-up companies. Additionally, these responsibilities include surveying University research and facilitating commercial collaborations for technology translation and expanding the IP portfolio of the University by encouraging and supporting invention disclosures and patent filings. His research focus areas include: medtech technology transfer valuation, collaborative innovation ecosystems, and faculty spin out companies.

Pankaj Desai, PhD, Professor and Director, Drug Development Graduate Program, College of Pharmacy, University of Cincinnati

Pankaj B. Desai is currently Professor of Pharmacokinetics and Biopharmaceutics and Director, Drug Development Graduate Program, College of Pharmacy, University of Cincinnati, Cincinnati, OH, with a secondary appointment in the Department of Hematology/Oncology, UC College of Medicine. He is also a co-founder and Chief Scientific Officer of Arogin Rx LLC, an Ohio based Start-up Company focused on the development of novel oncology drugs. Dr. Desai’s research interests include pre-clinical and clinical studies on drug metabolism, transport and pharmacokinetics. The current focus of his laboratory is on translational/experimental therapeutics research to facilitate the development and optimizing the clinical use of anti-cancer drugs. Dr. Desai directs a vigorous, extramurally funded research program and has authored numerous peer-reviewed publications. His research has been funded by the National Institutes of Health (NIH), Komen Foundation, American Cancer society and various pharmaceutical companies.

Bruce Halpryn, PhD, Chief Operating Officer, Myonexus Therapeutics

Dr. Halpryn co-founded Myonexus Therapeutics after several years each at N8 as COO, 28 years at P&G Pharma, cardiovascular research in Antarctica, + studying cardiovascular effects of spaceflight for NASA. He held numerous leadership roles in P&G including: creation + leadership of Early Phase New Drug Development Department; leadership of Regulatory Affairs for Pharma’s EU subsidiaries; creation & leadership of Technical & IP Due Diligence; creation and leadership of Pharma’s New Business Development/Open Innovation process. Dr. Halpryn played a key role in the evaluation and negotiation of all of P&G Pharma’s partnerships. He was key technical liaison to the VC community providing advice and identifying opportunities for P&G.

Takanori Takebe, MD, Associate Director of Commercial Innovation, Department of Pediatrics, Cincinnati Children’s

Dr. Takebe is an assistant professor at the Cincinnati Children’s Hospital Medical Center. Also, he holds a joint appointment at the Department of Regenerative Medicine, Yokohama City University in Japan, where he directs a translational program of human induced pluripotent stem cell (iPSC) based liver bud based approach for congenital liver disorders by developing a cGMP manufacturing platform. Dr. Takebe successfully administered more than six nationally funded projects, awarded number of prestigious awards such as NYSCF robertson investigator award, and produced high impact peer-reviewed publications from each project. His recent associate professor appointment, at the age 26, was one of the youngest recorded in Japan.

10:15 – Other Federal & Ohio Drug Discovery Resources

Elliot Reed, EIR, Faculty – College of Graduate Studies | REDIzone Program Manager, Northeast Ohio Medical University

Elliot Reed is responsible for creating a culture of innovation and entrepreneurship at Northeast Ohio Medical University and leading the public-private interactions between regional start-up life science companies and University researchers. His Entrepreneur in Residence responsibilities focus on providing early-stage commercial planning and fundraising support for REDizone companies and NEOMED faculty/students interested in start-up companies. Additionally, these responsibilities include surveying University research and facilitating commercial collaborations for technology translation and expanding the IP portfolio of the University by encouraging and supporting invention disclosures and patent filings. His research focus areas include: medtech technology transfer valuation, collaborative innovation ecosystems, and faculty spin out companies.

10:40 – Advancements/Showcase in Drug Discovery & Development – Industry

Moderated by John F. Lewis, Jr., President & CEO, BioOhio

John F. Lewis, Jr., is a 4th generation Ohioan, his family tracing Ohio roots to the mid 1800s. He is a licensed attorney with experience in international business, venture capital investments and economic development. John is an outspoken advocate for industry led, market facing academic/industry collaborations. During the last 16+ years with BioOhio, John has helped raise nearly $1 billion for Ohio bioscience entities. He was a founding partner of the First Fifty Fund and Ohio TechAngel Fund both based in Columbus. John has more than 18 years international experience, lived in Jamaica, Korea and China, the latter two with Perkin Elmer, while traveling to more than 42 others. John is a graduate of Miami (Ohio) University and Capital University Law School.

Kevin Peters, PhD, Chief Scientific Officer, Aerpio

Dr. Peters guided the early preclinical and clinical development of AKB-9778 while at Akebia and Aerpio, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Group Medical Director, CV and Metabolic Disease in Global and Discovery Medicine at Bristol Myers Squibb and head of Therapeutic Angiogenesis research at Proctor & Gamble Pharmaceuticals. Prior to that, Dr. Peters was an Associate Professor of Medicine and Pharmacology in the Division of Cardiology at Duke University Medical Center. Dr. Peters received his M.D. from the University of Iowa and was a Research Fellow and Adjunct Professor at the University of California, San Francisco. Dr. Peters has published broadly in the areas of growth factor receptor signaling and vascular biology and has led several preclinical programs to clinical proof of concept in vascular and metabolic diseases.

Jan Rosenbaum, PhD, Chief Scientific Officer, Airway Therapeutics

Dr. Jan Rosenbaum has more than 20 years of drug development experience. Jan held technical management positions in big pharma (P&G pharmaceuticals) where she led efforts on the development of small molecule, peptide, and protein therapeutics. She joined CincyTech in 2009 as Director of Life Sciences with responsibility for creating life science startup companies in the southwest Ohio region and has been involved with Airway since its initial financing round. Jan’s areas of expertise are in Molecular Pharmacology and Developmental Biology. She has authored over 50 publications and is an inventor on multiple US and foreign patents. Jan holds a Ph.D. in Pharmaceutical Chemistry from UCSF and a postdoctoral fellowship in Clinical Pharmacology from Stanford University.

Isaiah Shalwitz, VP of Business Development and Operations, Invirsa

Isaiah Shalwitz is a biostatistician and experienced program manager in pharmaceutical development. Isaiah worked in multiple aspects of pharmaceutical development during his eight-year tenure with Akebia Therapeutics. Most recently, Isaiah was the program manager for the team during non-clinical development, including IND enabling studies, of AKB-6899.

12:30 – Pre-IND Meeting Tasks

Ken Phelps, President & CEO, Camargo Pharmaceutical Services

In 2003, Ken Phelps applied more than three decades of industry experience to found Camargo Pharmaceutical Services in Cincinnati with Dr. Ruth Stevens (chief scientific officer and executive vice president). Today, Camargo partners with companies in more than 25 countries worldwide and has led the largest percentage of 505(b)(2) submissions of any team submitting to the FDA — Camargo has led more than 1100 Agency meetings and is the industry authority in 505(b)(2). Today, as a thought leader in the shifting landscape of drug development and emergent pathways around the globe, Phelps addresses the financial challenges of pharmaceutical companies caused by the generics cliff and routinely presents on the topic at events worldwide.

1:00 – Writing INDs

Dennis King, President and Founder, STATKING Clinical Services

Dennis W. King is currently responsible for marketing, contracting and overall management activities at STATKING. In the area of pharmaceutical and medical device statistics, Dr. King has interacted with FDA personnel at FDA committee meetings and FDA scientific advisory committee meetings on behalf of his clients. He has written protocols, Statistical Analysis Plans (SAPs), SAS Analysis Program Requirements Documents, final statistics reports, and the statistical portions of NDA and PMA submissions for many drug and device development programs. He has published over 30 technical articles in the area of clinical trials. He received his PhD in statistics in 1988 from Texas A&M University and his MS degree in statistics in 1980 from the University of Wyoming.

Donald G. Stump, PhD, DABT, Senior Director, Toxicology, Charles River Laboratories

Donald G. Stump, PhD, DABT, earned a B.S. in toxicology from the Philadelphia College of Pharmacy and Science (1985). In addition, Dr. Stump received a Ph.D. in Biochemistry from Vanderbilt University (1990) and post-doctoral training at the National Institutes of Health. In his role at Charles River Laboratories – Ashland, he oversees the General Toxicology, Developmental and Reproductive Toxicology, and Pharmacology and Discovery Services departments. Dr. Stump has published over 80 research articles and book chapters. He is currently an Associate Editor for the International Journal of Toxicology and is on the editorial board for both Birth Defects Research and Congenital Anomalies and has previously served on the editorial board of Reproductive Toxicology.

Douglas W. Balogh, PhD, Director, Navigant Consulting

Douglas W. Balogh, Ph.D., has over three decades of industry experience in drug product development and regulatory affairs.  Dr. Balogh has an extensive background in pharmaceutical manufacturing process development, formulation development, and analytical method development – as well as experience in preparation of CT materials, supply chain strategy, technology transfer, outsourcing, and associated FDA regulations. As a practicing scientist, Dr. Balogh had previously developed chemical processes for preparing clinical materials and commercialization of new pharmaceutical agents. His scientific leadership has included roles as Head of Discovery Chemistry, Bioprocess, and Technical Service groups; and leader of numerous Chemistry, Manufacturing, and Controls (“CMC”) Development teams – developing processes, methods, and formulations in full integration with preclinical, clinical, marketing, and regulatory strategies.

Keith Moore, PharmD, FCCP, BCPS, Chief Scientific Officer and Founder, ICIOMICS Life Sciences

Dr. Moore is a highly accomplished and driven international pharmaceutical development executive with broad-based expertise in biomedical research, preclinical and clinical drug-device development, strategic planning, product development, proof-of-concept execution, clinical trial implementation and monitoring (Phase I, II, III & IV), data management, statistics, medical safety management, medical writing, and regulatory compliance with frequent interactions with regulatory and scientific bodies (i.e. FDA, CDC, and WHO). He serves as a results-oriented innovator, with more than 10 drug/medical patents, who seeks to reduce the variation in an individual’s response to medications and biologic agents by tailoring therapy to a person’s genetics, improving efficacy, maximizing safety, and minimizing healthcare costs through patient-reported outcomes.

2:30 – Accelerating Drug Clinical Development

Steven Johnson, Vice President, Regulatory Affairs, Medpace

Dr. Steven B. Johnson is globally responsible for all regulatory affairs and medical writing activities at Medpace. Dr. Johnson completed his Bachelor of Science, Bachelor of Pharmacy, and Doctor of Pharmacy degrees from Washington State University. He has over 18 years of experience in regulatory drug development, of which eight were with the FDA as a clinical Pharmacology Reviewer, and eventually, a Master Reviewer in the Division of Metabolic and Endocrine Drug Projects. Focused therapeutic areas in which Dr. Johnson has experience include, but are not limited to, endocrinology, infectious disease, oncology, and immunology. He has gained extensive knowledge through his work with the following regulatory agencies: US FDA, EU National Authorities (e.g., DHMA, PEI, BfRM, MHRA); EMA (CHMP; PDCO); and Health Canada (PMDA).

3:00 – Legal, Ethical, Regulatory and Public Policy Concerns About New Advancements in Drug Discovery

Moderated by Leah Brownlee, Of Counsel, Global Corporate Practice, Life Sciences Industry Group, Squire Patton Boggs (US) LLP

Leah Brownlee is a member of Squire Patton Boggs’ Corporate Practice Group, where she advises corporate and securities law matters within the life sciences industry and more broadly, in the tech sector, including venture capital and strategic financing, public and private capital markets transactions, securities law compliance, stock exchange listing requirements, strategic intellectual property advice and corporate governance, and international business transactions. She also has expertise in counseling public and private companies in connection with other corporate transactions, including mergers, acquisitions, dispositions and joint ventures, manufacturing, distribution and research agreements, and on general business matters.

James Reed, Senior Patent Counsel, Squire Patton Boggs (US) LLP

James Reed, patent counsel in the Intellectual Property & Technology Practice Group, focuses on patents in the areas of automotive and aeronautical/aerospace systems, mechatronics, sensors, cybersecurity, medical devices and renewable energy (wind and solar), and patents having a machine learning/AI component. His practice emphasizes patent portfolio management and patenting strategy, due diligence and freedom-to-use, patent litigation and patent licensing. With a background in industry, degrees in aerospace engineering and applied mathematics, and more than 15 years as a practicing patent lawyer, James has built a solid reputation as a go-to source for solutions to patent-related problems or needs. Before entering the legal field, James worked for nearly 10 years as an aerospace engineering consultant to NASA.

Sarah Stec, Associate, Squire Patton Boggs (US) LLP

Sarah Stec is an associate in the Public Policy Practice in Washington DC. She has experience in assisting life sciences companies, including medical device and pharmaceutical companies, understanding new and evolving regulatory duties, including how those international regulations can work together, as well as providing guidance on international corporate accreditation and regulatory issues. Her unique approach to regulatory issues incorporates a deep understanding in the corresponding legal and quality issues, providing well-rounded solutions to clients in heavily regulated life sciences industries. Sarah is a member of the Regulatory Affairs Professionals Society (RAPS) and the Food and Drug Law Institute (FDLI).

Vyacheslav Vasilyev, Corporate Counsel, Zoetis

Vyacheslav “Slava” Vasilyev serves as Corporate Counsel for Kalamazoo, MI based Zoetis Inc., (formerly Pfizer Animal Health), the world’s largest producer of medicine and vaccinations for pets and livestock. In the role since 2013, Slava is responsible for a variety of intellectual property, transactional, governance, regulatory and contractual matters supporting the core Zoetis business. Vyacheslav previously worked as a Corporate Counsel for Pfizer after serving as an associate with two law firms dating back to 2005. He graduated from the Case Western Reserve University School of Law with his JD degree. He also earned a PhD degree from the University of California, San Diego in neurobiology and neurosciences as well as a BS degree from the University of Maryland in biology and biological sciences.

Northeast Ohio, May 22

9:30 – Introduction & Opening Remarks

Scott Clay, Meeting and Event Planner, BioOhio

Scott Clay has been in the hospitality and events industry for over fifteen years in every capacity possible, from universities, restaurants, and catering companies, to convention centers and his own entrepreneurial venture. When not creating fabulous BioOhio events, Scott is an active member of Central Ohio’s theater community, having the honor of working with some of the most talented artists this city has to offer. In addition, Scott operates his own micro-cakery, Scott’s Sugar Shack, specializing in large carved cakes, unique flavor pairings, and intricate designs. Scott holds a degree in Business from Franklin University, and Fine Arts from The Ohio State University.

9:35 – Legal, Ethical, Regulatory and Public Policy Concerns About New Advancements in Drug Discovery

Moderated by Leah Brownlee, Of Counsel, Global Corporate Practice, Life Sciences Industry Group, Squire Patton Boggs (US) LLP

Leah Brownlee is a member of Squire Patton Boggs’ Corporate Practice Group, where she advises corporate and securities law matters within the life sciences industry and more broadly, in the tech sector, including venture capital and strategic financing, public and private capital markets transactions, securities law compliance, stock exchange listing requirements, strategic intellectual property advice and corporate governance, and international business transactions. She also has expertise in counseling public and private companies in connection with other corporate transactions, including mergers, acquisitions, dispositions and joint ventures, manufacturing, distribution and research agreements, and on general business matters.

James Reed, Senior Patent Counsel, Squire Patton Boggs (US) LLP

James Reed, patent counsel in the Intellectual Property & Technology Practice Group, focuses on patents in the areas of automotive and aeronautical/aerospace systems, mechatronics, sensors, cybersecurity, medical devices and renewable energy (wind and solar), and patents having a machine learning/AI component. His practice emphasizes patent portfolio management and patenting strategy, due diligence and freedom-to-use, patent litigation and patent licensing. With a background in industry, degrees in aerospace engineering and applied mathematics, and more than 15 years as a practicing patent lawyer, James has built a solid reputation as a go-to source for solutions to patent-related problems or needs. Before entering the legal field, James worked for nearly 10 years as an aerospace engineering consultant to NASA.

Sarah Stec, Associate, Squire Patton Boggs (US) LLP

Sarah Stec is an associate in the Public Policy Practice in Washington DC. She has experience in assisting life sciences companies, including medical device and pharmaceutical companies, understanding new and evolving regulatory duties, including how those international regulations can work together, as well as providing guidance on international corporate accreditation and regulatory issues. Her unique approach to regulatory issues incorporates a deep understanding in the corresponding legal and quality issues, providing well-rounded solutions to clients in heavily regulated life sciences industries. Sarah is a member of the Regulatory Affairs Professionals Society (RAPS) and the Food and Drug Law Institute (FDLI).

Vyacheslav Vasilyev, Corporate Counsel, Zoetis

Vyacheslav “Slava” Vasilyev serves as Corporate Counsel for Kalamazoo, MI based Zoetis Inc., (formerly Pfizer Animal Health), the world’s largest producer of medicine and vaccinations for pets and livestock. In the role since 2013, Slava is responsible for a variety of intellectual property, transactional, governance, regulatory and contractual matters supporting the core Zoetis business. Vyacheslav previously worked as a Corporate Counsel for Pfizer after serving as an associate with two law firms dating back to 2005. He graduated from the Case Western Reserve University School of Law with his JD degree. He also earned a PhD degree from the University of California, San Diego in neurobiology and neurosciences as well as a BS degree from the University of Maryland in biology and biological sciences.

11:00 – Other Federal & Ohio Drug Discovery Resources

Angela W. Corona, PhD, Director, Business development, BioMotiv

Angela W. Corona brings to BioMotiv an expertise in a diverse range of life sciences and drug development fields. She has a major role in directing non-dilutive funding strategy to secure substantial funds for multiple BioMotiv portfolio companies, along with performing due diligence for new investment opportunities, and building strategic collaborations to promote the success of early stage therapeutics projects. Prior to joining BioMotiv, Dr. Corona was a Post-doctoral Research Fellow in the Alzheimer’s Disease Research Laboratory at Case Western Reserve University in Cleveland, OH. Dr. Corona completed her Ph.D. in Neuroscience at the Ohio State University and holds a B.S. in Biochemistry from Binghamton University.

Brad Lang, PhD, Executive in Residence, BioEnterprise

Brad Lang has over 12 years of experience in the regenerative medicine industry. As an Executive-in-Residence at BioEnterprise, Brad provides consulting to early stage pharmaceutical and biologic companies. He also serves the role of vice president of research at Convelo, a pharma company working on novel therapeutics for neurological disorders. Previously, he served as a scientist on the regenerative medicine team at Athersys, participating in the clinical advancement of its MultiStem system. Brad received his B.S. in Biology from the University of Wisconsin-Madison and Ph.D. in Neurosciences from Case Western Reserve University.

Elliot Reed, EIR, Faculty – College of Graduate Studies | REDIzone Program Manager, Northeast Ohio Medical University

Elliot Reed is responsible for creating a culture of innovation and entrepreneurship at Northeast Ohio Medical University and leading the public-private interactions between regional start-up life science companies and University researchers. His Entrepreneur in Residence responsibilities focus on providing early-stage commercial planning and fundraising support for REDizone companies and NEOMED faculty/students interested in start-up companies. Additionally, these responsibilities include surveying University research and facilitating commercial collaborations for technology translation and expanding the IP portfolio of the University by encouraging and supporting invention disclosures and patent filings. His research focus areas include: medtech technology transfer valuation, collaborative innovation ecosystems, and faculty spin out companies.

12:15 – Advancements/Showcase in Drug Discovery & Development – Industry

Stephen A Charles, PhD, Executive in Residence, BioEnterprise

As an Executive in Residence with BioEnterprise, Steve provides executive consulting to pharmaceutical, biologics, and diagnostics companies. Currently, he serves as the CEO and co–founder of SATOR Therapeutics, an early stage company with an oncolytic virus platform. Prior to this he served as CEO for Lobesity, an early stage company with a novel treatment for obesity; the CTO for Diasome Pharmaceuticals, a clinical stage company with a liver targeting technology for the treatment of diabetes; and the CTO for Atalantos Biotechnology, an early stage company with a non–addictive therapeutic designed specifically for drug and/or alcohol detox that results in rapid physical restoration and mental clarity and provides an optimal framework for the therapeutic work necessary for sustained recovery.

Carl Hulit, Vice President of Research and Development, Nortis

Carl Hulit is Vice President of R&D at Nortis Inc. He has a degree in Mechanical Engineering from Duke University. He has experience in product design in the medical device, consumer electronics and aerospace industries at companies including Philips, Microsoft and Boeing. He joined Nortis in 2014 where he leads product development for a range of commercial organ on a chip technologies.

1:30 – Advancements in Drug Discovery & Development – Academia

Moderated by Elliot Reed, EIR, Faculty – College of Graduate Studies | REDIzone Program Manager, Northeast Ohio Medical University

Elliot Reed is responsible for creating a culture of innovation and entrepreneurship at Northeast Ohio Medical University and leading the public-private interactions between regional start-up life science companies and University researchers. His Entrepreneur in Residence responsibilities focus on providing early-stage commercial planning and fundraising support for REDizone companies and NEOMED faculty/students interested in start-up companies. Additionally, these responsibilities include surveying University research and facilitating commercial collaborations for technology translation and expanding the IP portfolio of the University by encouraging and supporting invention disclosures and patent filings. His research focus areas include: medtech technology transfer valuation, collaborative innovation ecosystems, and faculty spin out companies.

Anthony J. Berdis, PhD, Associate Professor of Chemistry and Biology, Cleveland State University | Chief Scientific Officer, Co-Founder, Red5 Pharmaceuticals

Dr. Berdis received his Ph.D. in Biochemistry from the University of North Texas. After receiving his doctoral degree, Dr.Berdis received an NIH sponsored postdoctoral fellowship to pursue research under the direction of Professor Stephen J. Benkovic, a world renowned enzymologist and bio-organic chemist at Pennsylvania State University. Dr. Berdis is a tenured faculty member in the Department of Chemistry and the Center for Gene Regulation in Health and Disease at Cleveland State University. He is an internationally recognized expert in the field of the synthesis and biological testing of novel nucleoside and nucleotide analogs as both therapeutic and diagnostic agents target DNA polymerase activity, publishing over 70 research papers and book chapters. His research has been funded by numerous agencies including the National Institutes of Health, the National Science Foundation, the Department of Defense, and the American Cancer Society.

Stephanie Ham, PhD, CEO & Co-Founder, OncoSolutions

Dr. Stephanie Ham graduated with her Ph.D. in Biomedical Engineering from The University of Akron in 2017 and a B.S. in Chemical Engineering from Miami University in 2012. Her dissertation work included developing and testing the 3D cancer cell model technology that became the basis for OncoSolutions. Through an extensive NSF I-Corps Teams customer discovery program, in which Dr. Ham served as the entrepreneurial lead, it became apparent that a strong unmet need exists in the cancer drug discovery market that OncoSolutions’ technology could address. She has since led the formation of OncoSolutions and raised its initial funding to build its lab located in Akron at the Bounce Innovation Hub and perform industry validation studies. Dr. Ham has a strong background in technology development and optimization, cancer biology, and entrepreneurship.

Moo-Yeal Lee, PhD, Associate Professor, Cleveland State University

Dr. Lee received his Ph.D. from KAIST, South Korea, and worked at Tokyo Institute of Technology as a postdoctoral fellow supported by Japan Society for the Promotion of Science (JSPS). He moved to the United States and worked at Rensselaer Polytechnic Institute and Solidus Biosciences, Inc. before joining CSU in 2013. Dr. Lee has been awarded multiple grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF) for his innovative research for testing potentially toxic compounds rapidly on microarray biochip platforms. He is selected as one of finalists in Transform Tox Testing Challenge supported by US Environmental Protection Agency (EPA) and NIH. He is also selected for I-Corps at Ohio and TeCK Fund for his effort to commercialize the biochip platforms. He has published 60 research articles in peer-reviewed journals, including the prestigious Nature Communications, 18 patents and patent applications, 4 book chapters, and 1 book.

Events